Literature DB >> 25502741

Superselective microcoil embolization in severe intractable epistaxis: an analysis of 12 consecutive cases from an otorhinolaryngologic and an interventional neuroradiologic point of view.

D U Seidel1, S Remmert2, F Brassel3, M Schlunz-Hendann3, D Meila4,5.   

Abstract

From 2006 to 2013, 12 patients with severe epistaxis refractory to prior conservative and surgical therapy were treated by superselective embolization of nasal arteries. Supersoft platinum microcoils with smallest diameters were used as the sole embolic agent in all cases. Coils were applied far distally in a stretched position for obtaining ideal target vessel superselectivity. The objective of this study is to evaluate efficacy and complications of superselective coil embolization for treatment of severe intractable epistaxis and to discuss results from an otorhinolaryngologic and an interventional neuroradiologic point of view. Retrospectively, all epistaxis inpatients between 2006 and 2013 were identified and subdivided by form of treatment: conservative, surgical and interventional therapy. Medical records of interventionally treated patients were reviewed for demographics, medical history, risk factors, clinical data, complications and short-term success, and patients were followed up for long-term success. Mean follow-up was 37 months. In 12 patients, 14 embolizations were carried out, with short-term success in 9 patients (75%), while early post-interventional rebleeding occurred in 3 patients (25%). Of 9 patients with short-term success, 1 died during stay, 1 was lost to follow-up and 1 had minor re-bleeding after 30 months. Six patients had short-term and long-term success. Before the first embolization, 3 ± 1 conservative and/or surgical procedures had been undertaken. Length of stay was 12.8 ± 3.6 days. 8 patients (67%) received red cell concentrates. Most frequent complications were mucosal damage and nasal pain, but these were related to repeated packing and surgery. Typical embolic complications as neurological or visual impairment or soft tissue necrosis were not observed in any patient. From the otorhinolaryngologic point of view, surgery is the treatment of choice in severe refractory epistaxis, but in case of repeated failure, superselective microcoil embolization is a valuable addition to the therapeutic spectrum. From the interventional neuroradiologic point of view, superselective microcoil embolization is an effective, well tolerable and safe procedure and complications may be reduced in comparison to microparticle embolization. Modern supersoft microcoils with smallest diameters enable ideal superselectivity of the target vessels.

Entities:  

Keywords:  Angiography; Complications; Endovascular intervention; Internal maxillary artery; Intractable epistaxis; Microcoils; Sphenopalatine artery; Superselective embolization

Mesh:

Year:  2014        PMID: 25502741     DOI: 10.1007/s00405-014-3427-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

Review 1.  Endovascular treatment of epistaxis.

Authors:  P W A Willems; R I Farb; R Agid
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-16       Impact factor: 3.825

2.  Idiopathic intractable epistaxis: endovascular therapy.

Authors:  J Vitek
Journal:  Radiology       Date:  1991-10       Impact factor: 11.105

Review 3.  Comparison of internal maxillary artery ligation versus embolization for refractory posterior epistaxis.

Authors:  M M Cullen; T A Tami
Journal:  Otolaryngol Head Neck Surg       Date:  1998-05       Impact factor: 3.497

4.  Selective endovascular embolization for refractory idiopathic epistaxis is a safe and effective therapeutic option: technique, complications, and outcomes.

Authors:  José E Cohen; Samuel Moscovici; John M Gomori; Ron Eliashar; Jeffrey Weinberger; Eyal Itshayek
Journal:  J Clin Neurosci       Date:  2012-02-23       Impact factor: 1.961

5.  Microcatheter embolization of intractable idiopathic epistaxis.

Authors:  M Leppänen; S Seppänen; J Laranne; K Kuoppala
Journal:  Cardiovasc Intervent Radiol       Date:  1999 Nov-Dec       Impact factor: 2.740

Review 6.  Epistaxis: update on management.

Authors:  Louise Melia; Gerald W McGarry
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2011-02       Impact factor: 2.064

7.  On the effectiveness of treatment options in epistaxis: an analysis of 678 interventions.

Authors:  M B Soyka; G Nikolaou; K Rufibach; D Holzmann
Journal:  Rhinology       Date:  2011-10       Impact factor: 3.681

8.  Endovascular treatment of epistaxis: indications, management, and outcome.

Authors:  Katharina Strach; Andreas Schröck; Kai Wilhelm; Susanne Greschus; Henriette Tschampa; Markus Möhlenbruch; Claas P Naehle; Mark Jakob; Andreas O H Gerstner; Friedrich Bootz; Hans H Schild; Horst Urbach
Journal:  Cardiovasc Intervent Radiol       Date:  2011-04-07       Impact factor: 2.740

9.  Impact of vessel choice on outcomes of polyvinyl alcohol embolization for intractable idiopathic epistaxis.

Authors:  Ravi Gottumukkala; Yasha Kadkhodayan; Christopher J Moran; De Witte T Cross; Colin P Derdeyn
Journal:  J Vasc Interv Radiol       Date:  2012-11-30       Impact factor: 3.464

Review 10.  Radiological diagnosis and management of epistaxis.

Authors:  Antonín Krajina; Viktor Chrobok
Journal:  Cardiovasc Intervent Radiol       Date:  2014-02       Impact factor: 2.740

View more
  3 in total

Review 1.  Endovascular Treatment of Epistaxis.

Authors:  Joan C Wojak
Journal:  Semin Intervent Radiol       Date:  2020-05-14       Impact factor: 1.513

2.  Spontaneous sphenopalatine pseudoaneurysm: recurrent epistaxis in a patient with cryptogenic vasculopathy.

Authors:  Samantha Goh; Louisa Ritchie; Theo Joseph; Jocelyn Brookes
Journal:  BMJ Case Rep       Date:  2015-06-25

3.  A blind area of origins of epistaxis: technical or cognitive?

Authors:  Wei Wei; Yuting Lai; Chaoping Zang; Jiqin Luo; Bijun Zhu; Quan Liu; Ying Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-24       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.